Processing timeline
25
days
Filed
18 May 2026
Decision Due
TBC
Est decision date: 14 June 2026. Based on 25 decided Industrial Manufacturing notifications.
Acquirer(s)
Eli Lilly and Company IRS Employer Identification Number - 35-0470950
Target(s) or Vendor(s)
Kelonia Therapeutics, Inc.
Other parties
Shareholder Representative Services LLC, Kang Acquisition Corporation
US-based pharmaceutical company Eli Lilly and Company proposes to acquire 100% of the shares in US-based clinical-stage biotechnology company Kelonia Therapeutics, Inc. Kelonia focuses on developing genetic medicines, including CAR-T therapies for oncology. Eli Lilly has an Australian subsidiary.
Eli Lilly and Company ( Eli Lilly ) proposes to acquire 100% of the issued shares in Kelonia Therapeutics, Inc ( Kelonia Therapeutics ) (the Acquisition ). Eli Lilly is a US-based pharmaceutical company, which discovers, develops, manufactures and markets human pharmaceutical products for various therapeutic areas, including diabetes, oncology, immunology and neuroscience. Eli Lilly is headquartered in Indianapolis, US and is publicly listed on the New York Stock Exchange. Eli Lilly has an Australian subsidiary that registers and markets medicine in Australia. Kelonia Therapeutics is a US-based clinical-stage biotechnology company focused on the development of genetic medicines using its in vivo gene placement system (iGPS). Kelonia Therapeutics is developing a pipeline of lentiviral-based in vivo CAR-T therapies primarily for oncology indications. Its lead asset (KLN-1010) is a clinical-stage (Phase 1) that uses iGPS to deliver an anti-BCMA CAR to T cells for treatment of multiple myeloma.